LENZ

LENZ Therapeutics Inc

Add to Watchlist

Advanced Chart

39.325

+0.555(1.432%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

39.325

Open

39.325

VWAP

39.39

Vol

52.31K

Mkt Cap

1.11B

Low

39.325

Amount

2.06M

EV/EBITDA(TTM)

Total Shares

28.52M

896.28M

EV/OCF(TTM)

P/S(TTM)

LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.

8 Analyst Rating

25.34% Upside

Wall Street analysts forecast LENZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LENZ is 49.29 USD with a low forecast of 36.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

25.34% Upside

Current: 39.325

Low

36.00

Averages

49.29

High

60.00

25.34% Upside

Current: 39.325

Low

36.00

Averages

49.29

High

60.00

BofA

Jason Gerberry

Buy

maintain

$44 -> $53

2025-08-03

Reason

BofA

Jason Gerberry

Price Target

$44 -> $53

2025-08-03

maintain

Buy

Reason

BofA analyst Jason Gerberry raised the firm's price target on Lenz Therapeutics to $53 from $44 and keeps a Buy rating on the shares. The firm cites the company's Vizz FDA approval and Q2 report the target increase. It believes Lenz's peak sales opportunity for Vizz is being underappreciated at current share levels.

Citi

Buy

maintain

$49 -> $52

2025-08-01

Reason

Citi

Price Target

$49 -> $52

2025-08-01

maintain

Buy

Reason

Citi raised the firm's price target on Lenz Therapeutics to $52 from $49 and keeps a Buy rating on the shares after the FDA approved Vizz a week earlier than the action date. The firm says Lenz has a week "head-start" to start commercialization of the drug.

H.C. Wainwright

NULL -> Buy

upgrade

$38 -> $48

2025-07-28

Reason

H.C. Wainwright

Price Target

$38 -> $48

2025-07-28

upgrade

NULL -> Buy

Reason

H.C. Wainwright raised the firm's price target on Lenz Therapeutics to $48 from $38 and keeps a Buy rating on the shares. The firm sees positive key opinion leader sentiment for LNZ100, a daily eye drop for presbyopia, heading into the August 8 FDA action date.

HC Wainwright & Co.

Matthew Caufield

Strong Buy

Reiterates

$30

2025-04-16

Reason

HC Wainwright & Co.

Matthew Caufield

Price Target

$30

2025-04-16

Reiterates

Strong Buy

Reason

Piper Sandler

Biren Amin

Buy

Maintains

$38 → $51

2025-04-14

Reason

Piper Sandler

Biren Amin

Price Target

$38 → $51

2025-04-14

Maintains

Buy

Reason

Piper Sandler analyst Biren Amin assumed coverage of Lenz Therapeutics (LENZ) with an Overweight rating with a price target of $51, up from $38, on the potential of LNZ100, an acelidine-based topical eyedrop for presbyopia, which affects about 128M individuals in the U.S. With the NDA accepted last October and a PDUFA assigned for August 8, 2025, LNZ100 is on track to launch in Q4 2025. The firm believes LNZ100 has a best-in-indication profile, superior to AbbVie's (ABBV) Vuity and Tenpoint's Bramichol. Piper's model estimates U.S. sales of $58M in 2026, growing to $592M by 2035.

Citigroup

Yigal Nochomovitz

Strong Buy

Maintains

$44 → $47

2025-03-20

Reason

Citigroup

Yigal Nochomovitz

Price Target

$44 → $47

2025-03-20

Maintains

Strong Buy

Reason

Citi raised the firm's price target on Lenz Therapeutics to $47 from $44 and keeps a Buy rating on the shares. The firm says the company "continues to march forward with discipline" towards the August 8 FDA action date for LNZ100 in aceclidine eyedrop for presbyopia. Citi continues to forecast high likelihood of approval. The "recent and uneventful" mid-cycle review in further notched up the firm's conviction, driving the target higher, the analyst tells investors in a research note.

See All Ratings

Valuation Metrics

The current forward P/E ratio for LENZ Therapeutics Inc (LENZ.O) is -12.69, compared to its 5-year average forward P/E of -10.33. For a more detailed relative valuation and DCF analysis to assess LENZ Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-10.33

Current PE

-12.69

Overvalued PE

-8.19

Undervalued PE

-12.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-7.91

Current EV/EBITDA

-10.55

Overvalued EV/EBITDA

-5.15

Undervalued EV/EBITDA

-10.68

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

53.34

Current PS

49.86

Overvalued PS

105.17

Undervalued PS

1.51